The Correlation Between Ovarian Function and Serum Biomarkers

Launched by SHI YUN · Oct 18, 2023

Keywords

ClinConnect Summary

This clinical trial is studying how ovarian function relates to certain blood markers in women. The researchers want to understand the differences in these markers between women who have normal ovarian function and those with conditions like Premature Ovarian Insufficiency (POI) or Diminished Ovarian Reserve (DOR). By looking at these differences, they hope to learn more about how aging and other factors might affect ovarian health.

To participate in this study, women aged 18 to 45 who either have normal ovarian function or have been diagnosed with POI or DOR may be eligible, provided they meet specific health criteria. Participants will have their blood tested to measure various markers, and they can expect a supportive environment where their health and well-being are prioritized. It's important to note that women who are pregnant, breastfeeding, or have certain health issues will not be able to join the study. This research could help improve understanding of female reproductive health and lead to better treatments in the future.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • 1. The selection criteria for healthy individuals are follows.
• • women aged 18-45.
• • Basic FSH\<10IU/L, and AMH is within the normal range.
• • Regular menstruation.
• • Agree and sign an informed consent form.
• • 2. The selection criteria for DOR patients are follows.
• • women aged 18-45.
• • For two consecutive menstrual cycles, 25 ≥ basal FSH ≥ 10IU/L or AMH\<1.1ng/ml.
• • Agree and sign an informed consent form.
• • 3. Selection criteria for POI patients are follows.
• • 18 ≤ females aged \<40 years old.
• • Two consecutive menstrual cycles with basal FSH\>25IU/L or AMH\<1.1ng/ml.
• • Agree and sign an informed consent form.
• Exclusion Criteria:
• • 1. Patients with congenital gonadal developmental abnormalities or a family history similar to "early menopause".
• • 2. Patients with acquired organic lesions or decreased ovarian function caused by ovarian surgery.
• • 3. Patients who have undergone artificial cycle therapy with Western medicine or other endocrine treatments within the past three months.
• • 4. Patients with severe primary diseases and mental disorders such as crdiovascular, cerebrovascular, liver, kidney, and hematopoietic system.
• • 5. Patients during lactation or pregnancy.
• • 6. Patients who are allergic to the drugs used in this study or have a history of allergic reactions to traditional Chinese medicine.
• • Those who meet any of the above 5 criteria for DOR and POI will be excluded and not included in this study. The exclusion criteria for healthy subjects are as (1), (3), (4), and (5).